Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120781 · ClinicalTrials.gov registry record · Phase 2
Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia
A Phase 2 study, sponsored by Castle Creek Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT02120781 is a Phase 2 study that has completed, run by Castle Creek Biosciences. The registered enrollment target is 21 participants.
The verdict
NCT02120781, a Phase 2 study, has completed, sponsored by Castle Creek Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the safety of azficel-T treatment for dysphonia related to vocal fold function and to evaluate the efficacy of azficel-T for the treatment of dysphonia related to vocal fold function.
Interventions
- DRUG Placebo
- BIOLOGICAL Azficel-T (autologous fibroblasts)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120781
The ClinicalTrials.gov registry entry for NCT02120781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02120781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120781 about?
NCT02120781 is a clinical study titled "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia". The objectives of this study are to assess the safety of azficel-T treatment for dysphonia related to vocal fold function and to evaluate the efficacy of azficel-T for the treatment of dysphonia related to vocal fold function.
What is the current status of trial NCT02120781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2014-03. Estimated completion is 2016-12-21.
What interventions are being tested in trial NCT02120781?
The interventions under investigation include: Placebo (DRUG), Azficel-T (autologous fibroblasts) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02120781?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.